Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News
Financial Results · Q3 2026

Inogen Q3 2026 Results: Net Loss of $16.2M, Loss Widens

Inogen Inc. reported a net loss of $16.2 million for the third quarter of 2026, compared to a $5.3 million loss in the prior year, driven by a $10.6 million impairment charge. Total revenue for the quarter decreased slightly to $77.2 million, while the company's cash position declined to $81.8 million as of September 30, 2026.

Q3 2026 at a glance · $ million
MetricQ3 2026Q3 2025
Revenue77.279.1
Gross profit34.036.2
Profit before tax-14.6-3.8
Net income-16.2-5.3
EPS (diluted, $ a share)$-0.61$-0.20

A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.

Growth and margins
Revenue, year on year-2.4%
Gross margin44.1%
Operating margin-20.2%
Source

10-Q filed with the SEC, NASDAQ: INGN. Figures from the filing's XBRL data; summary written with AI assistance from the filing.

Read the filing ↗

Inogen Inc: key numbers

Share price
$5.63Close, Nov 16
Market cap
$146M
Shares outstanding
26MLatest SEC cover page
Sector
Industrial Applications and Services
Industry
Orthopedic, Prosthetic & Surgical Appliances & SuppliesSIC 3842

Today's reference numbers, updated daily. Not a valuation or a recommendation.

More from Inogen Inc

All →
4:13 PM ET 8-K
Leadership Change

Inogen Leadership Change

Inogen appointed current COO Andy Reding as President and CEO and a member of the Board of Directors, effective October 30, 2026. He succeeds Kevin R.M. Smith, whose role as an officer and employee ended on the same date. The transition occurs as the company focuses on a more streamlined commercial model following the divestiture of its U.S. rental business.

4:10 PM ET 8-K
Divestiture

Inogen Divestiture to Rotech Healthcare Inc. for $24.8M

Inogen agreed to sell substantially all assets of its U.S. oxygen rental business to Rotech Healthcare for an estimated $24.8 million. The divestiture is intended to streamline Inogen's commercial model and shift focus toward its product supply business, supported by a new long-term supply agreement with Rotech. Upon closing, Inogen will also increase its share repurchase authorization from $30 million to $45 million.

Value
$24.8M
Counterparty
Rotech Healthcare Inc.

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.